Home > Drugs A – Z > Mycophenolate (By injection)

Mycophenolate (By injection)

Prevents your body from rejecting an organ after transplant by suppressing your immune system.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Mycophenolate injection belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity in patients who receive organ transplants (eg, kidney, heart, or liver). When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ. Mycophenolate injection prevents the… Read more
Brand names include
Cellcept
Other forms
By mouth, Oral route
Drug classes About this
Immune Suppressant

What works? Research summarized

Evidence reviews

Mycophenolate mofetil for relapsing‐remitting multiple sclerosis

Multiple sclerosis (MS) is an immune‐mediated disease of the central nervous system. Preliminary data show that mycophenolate mofetil (MMF), an immunosuppressive agent, might be beneficial for MS patients. The authors of this review evaluated the efficacy and safety of MMF in patients with relapsing‐remitting MS. Only one small study met the inclusion criteria, and it compared MMF versus placebo in 26 interferon β‐1a–treated patients. The results showed no evidence favoring MMF in reducing relapses or preventing disability progression after a 12‐month follow‐up period. No data were available at 24 months. All patients receiving MMF suffered from gastrointestinal upset, and one had a transient diarrhea, but no serious adverse effects were reported.

Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation is a procedure in which a portion of a healthy donor's stem cells (cells that can develop into various types of blood cells) or bone marrow is obtained and prepared for intravenous infusion. Hematopoietic stem cells are taken from a healthy donor and transplanted into the patient (recipient). People undergoing allogeneic hematopoietic stem cell transplantation are at risk of developing graft‐versus‐host disease (GVHD). GVHD results when the transplanted cells from the donor (graft) attack the recipient's (host) body cells because they perceive the recipient's body as foreign. Mycophenolate mofetil and methotrexate are two drugs often used to suppress the human body's reaction against the graft (immune response) and prevent GVHD. We conducted a systematic review of three randomized controlled trials (RCTs, which are clinical studies where people are randomly put into one of two or more treatment groups) that compared mycophenolate mofetil versus methotrexate for use in preventing GVHD among 174 participants. We searched for the relevant studies in March 2014.

Effectiveness and safety of mycophenolate mofetil for IgA nephropathy: a meta-analysis

Bibliographic details: Yang Q, Ding H, Wang ZQ.  Effectiveness and safety of mycophenolate mofetil for IgA nephropathy: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012; 12(11): 1354-1360 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=20121112

See all (104)

Summaries for consumers

Mycophenolate mofetil for relapsing‐remitting multiple sclerosis

Multiple sclerosis (MS) is an immune‐mediated disease of the central nervous system. Preliminary data show that mycophenolate mofetil (MMF), an immunosuppressive agent, might be beneficial for MS patients. The authors of this review evaluated the efficacy and safety of MMF in patients with relapsing‐remitting MS. Only one small study met the inclusion criteria, and it compared MMF versus placebo in 26 interferon β‐1a–treated patients. The results showed no evidence favoring MMF in reducing relapses or preventing disability progression after a 12‐month follow‐up period. No data were available at 24 months. All patients receiving MMF suffered from gastrointestinal upset, and one had a transient diarrhea, but no serious adverse effects were reported.

Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation is a procedure in which a portion of a healthy donor's stem cells (cells that can develop into various types of blood cells) or bone marrow is obtained and prepared for intravenous infusion. Hematopoietic stem cells are taken from a healthy donor and transplanted into the patient (recipient). People undergoing allogeneic hematopoietic stem cell transplantation are at risk of developing graft‐versus‐host disease (GVHD). GVHD results when the transplanted cells from the donor (graft) attack the recipient's (host) body cells because they perceive the recipient's body as foreign. Mycophenolate mofetil and methotrexate are two drugs often used to suppress the human body's reaction against the graft (immune response) and prevent GVHD. We conducted a systematic review of three randomized controlled trials (RCTs, which are clinical studies where people are randomly put into one of two or more treatment groups) that compared mycophenolate mofetil versus methotrexate for use in preventing GVHD among 174 participants. We searched for the relevant studies in March 2014.

Treatments that suppress or modify the immune system for multifocal motor neuropathy

We reviewed the evidence for the benefits and harms of treatments that suppress or modify the immune system in multifocal motor neuropathy (MMN).

See all (25)

PubMed Health Blog...

read all...